BioPharmica, Ansell, Sonic, iSOFT, Progen, pSivida
BioPharmica, Ansell, Sonic, iSOFT, Progen, pSivida
Progen working on polyamine analogues for DNA demethylases, cell proliferation
Progen working on polyamine analogues for DNA demethylases, cell proliferation
Pharmaxis, Novogen, Progen, IDT, Clinuvel
Pharmaxis, Novogen, Progen, IDT, Clinuvel
Cellestis, Mesoblast, Tissue Therapies, Progen, Probiotec
Cellestis, Mesoblast, Tissue Therapies, Progen, Probiotec
Pharmaxis, Cochlear, CSL, HeartWare, Sirtex, Progen
Pharmaxis, Cochlear, CSL, HeartWare, Sirtex, Progen
Progen, Cytopia, Avexa, Acrux, Biota, Cellestis
Progen, Cytopia, Avexa, Acrux, Biota, Cellestis
Cochlear, CSL, Progen, Genera Biosystems, Peplin
Cochlear, CSL, Progen, Genera Biosystems, Peplin
Progen forced to drop Avexa merger after overwhelming no vote
Progen forced to drop Avexa merger after overwhelming no vote
Cytopia calls for board spill and offers merger for troubled Progen
Cytopia calls for board spill and offers merger for troubled Progen
Independent advisory firm to help Progen with planning following termination of PI88 study.
Independent advisory firm to help Progen with planning following termination of PI88 study.
Massive share price plunge as Progen abandons lead compound trial
Massive share price plunge as Progen abandons lead compound trial
The share price of Queensland biotech company Progen Industries has almost tripled in less than six months following promising Phase II clinical trial results for its lead cancer compound and the expectation of more good news in the near future.
